What Quanterix (QTRX) Said on Its Q3 Earnings Call
Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.
How this was made

The 30-second read
Why it matters
The earnings release adds new financial data and guidance, which is the primary catalyst for short‑term trading decisions.
Market read
First‑time earnings disclosure for Q3, providing fresh guidance and cash outlook for investors.
What to watch
Potential upside from new Medicaid reimbursement and upcoming FDA discussions may not be fully priced in.
Background
Quanterix is a life‑sciences company developing ultra‑sensitive immunoassay platforms; the Q3 call covered financial results and product updates.
Ticker impact
Quanterix reported Q3 net loss of $21.6M, updated guidance and cash outlook, making the earnings release the primary news for the ticker.
likely modest pressure as the market prices in the loss and unchanged guidance
The company posted a larger-than-expected loss, but maintained its cash and margin guidance, which typically limits large moves.
Market effects
Provides insight into the diagnostics and biotech instrumentation sector's margin pressures.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche diagnostic market participants.
Counterpoint
If investors focus on cash runway and upcoming product launches, the stock could be undervalued despite the loss.
Key entities
- companyQuanterix Corporation
NASDAQ‑listed diagnostics platform provider.

